EP1423144A4 - METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASE - Google Patents
METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASEInfo
- Publication number
- EP1423144A4 EP1423144A4 EP02753530A EP02753530A EP1423144A4 EP 1423144 A4 EP1423144 A4 EP 1423144A4 EP 02753530 A EP02753530 A EP 02753530A EP 02753530 A EP02753530 A EP 02753530A EP 1423144 A4 EP1423144 A4 EP 1423144A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cd40r
- interrupting
- compounds
- treatment
- signal transmission
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 108010029697 CD40 Ligand Proteins 0.000 title 1
- 102100032937 CD40 ligand Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000008054 signal transmission Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31111501P | 2001-08-10 | 2001-08-10 | |
| US311115P | 2001-08-10 | ||
| PCT/US2002/027035 WO2003014328A2 (en) | 1999-06-01 | 2002-08-12 | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1423144A2 EP1423144A2 (en) | 2004-06-02 |
| EP1423144A4 true EP1423144A4 (en) | 2006-08-02 |
Family
ID=32298094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02753530A Withdrawn EP1423144A4 (en) | 2001-08-10 | 2002-08-12 | METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASE |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1423144A4 (en) |
| AU (1) | AU2002313811A1 (en) |
| CA (1) | CA2467919A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023590A2 (en) * | 1998-10-20 | 2000-04-27 | Georgetown University Medical Center | INHIBITION OF CD40-MEDIATED NFλB ACTIVATION |
| WO2001096397A2 (en) * | 2000-06-09 | 2001-12-20 | Biogen, Inc. | Cd154 variants and uses thereof |
-
2002
- 2002-08-12 EP EP02753530A patent/EP1423144A4/en not_active Withdrawn
- 2002-08-12 CA CA002467919A patent/CA2467919A1/en not_active Abandoned
- 2002-08-12 AU AU2002313811A patent/AU2002313811A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023590A2 (en) * | 1998-10-20 | 2000-04-27 | Georgetown University Medical Center | INHIBITION OF CD40-MEDIATED NFλB ACTIVATION |
| WO2001096397A2 (en) * | 2000-06-09 | 2001-12-20 | Biogen, Inc. | Cd154 variants and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| STUBER ECKHARD ET AL: "Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion", BIOSIS, 1996, XP002189392 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1423144A2 (en) | 2004-06-02 |
| CA2467919A1 (en) | 2003-02-20 |
| AU2002313811A1 (en) | 2003-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60231601D1 (en) | DEVICE AND METHOD FOR TREATMENT | |
| EP1469871A4 (en) | METHOD FOR TREATING APOPTOSIS AND COMPOSITIONS THEREFOR | |
| EP1651164A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES | |
| EP1482962A4 (en) | METHOD FOR THE TREATMENT OF TRX-MEDIATED ILLNESSES | |
| EP1701664A4 (en) | SYSTEM AND METHOD FOR THE TREATMENT OF TISSUE | |
| DE60227095D1 (en) | COMPOSITIONS AND METHODS FOR TREATING SEPARATED GIPS | |
| DE60239796D1 (en) | PROCESS AND DEVICE FOR SAFE TRANSCODING | |
| DE60138129D1 (en) | APPARATUS FOR THE TREATMENT OF TEETH | |
| EP1507765A4 (en) | METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM AND NEW COMPOUNDS SUITABLE THEREFOR | |
| DE60135049D1 (en) | Method and device for improved chamber cleaning | |
| DE60143831D1 (en) | TAILORED ROHTEIL AND METHOD FOR THE PRODUCTION OF THE PART | |
| DE60116035D1 (en) | Process and apparatus for wastewater treatment | |
| DE60235578D1 (en) | TIRE TREATMENT METHOD | |
| DE60227877D1 (en) | Method and device for thermal treatment of substrates | |
| DE60208186D1 (en) | CHINAZOLIN AND CHINAZOLE-SEAL COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED ILLNESSES | |
| DE50210076D1 (en) | METHOD AND DEVICE FOR CONVERSION OF VIDEO SIGNALS | |
| DE60233221D1 (en) | METHOD FOR CLEANING HIGHER DIAMOND-STRUCTURAL COMPOUNDS AND THESE PREPARATIONS CONTAINING THEREOF | |
| DE60142605D1 (en) | Method and device for plasma treatment | |
| DE60218451D1 (en) | 15-KETO-PROSTAGLANDINE FOR THE TREATMENT OF DRUG-INDUCED OBSTIPATION | |
| DE60122839D1 (en) | Process for the treatment of chromate polluted wastewater | |
| DE60223688D1 (en) | METHOD FOR THE TREATMENT OF MULTIPLE MYELOMA | |
| ATA17552001A (en) | METHOD FOR TREATING ACID WASTE | |
| DE60014876D1 (en) | COMPOUNDS AND METHODS FOR TREATING ASTHMA, ALLERGY AND INFLAMMATORY DISEASES | |
| EP1487480A4 (en) | FUSION MOLECULES AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES | |
| DE50214806D1 (en) | METHOD AND DEVICE FOR EXHAUSTION TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20040309 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20060705 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/68 20060101ALI20060629BHEP Ipc: G01N 33/50 20060101ALI20060629BHEP Ipc: A61K 39/00 20060101ALI20060629BHEP Ipc: A61K 38/00 20060101AFI20060629BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ROSKAMP RESEARCH LLC |
|
| 17Q | First examination report despatched |
Effective date: 20080303 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20100302 |